235 results on '"Aiba, Setsuya"'
Search Results
2. Cohort study of subclinical sensitization against galactose‐α‐1,3‐galactose in Japan: Prevalence and regional variations.
- Author
-
Nakagawa, Yusei, Chinuki, Yuko, Ogino, Ryohei, Yamasaki, Kenshi, Aiba, Setsuya, Ugajin, Tsukasa, Yokozeki, Hiroo, Kitamura, Kaoru, and Morita, Eishin
- Abstract
Sensitization to galactose‐α‐1,3‐galactose (α‐Gal) leads to the development of α‐Gal syndrome, which includes red meat allergy and cetuximab‐induced anaphylaxis. Since tick bites represent the main cause of α‐Gal sensitization, it was speculated that sensitization to α‐Gal occurs throughout Japan. However, few cohort studies have investigated α‐Gal sensitization in Japan. Therefore, we aimed to elucidate the subclinical sensitization rate to α‐Gal in Japan. Sera were obtained from 300 participants without food or cetuximab allergy at Shimane University Hospital (Shimane prefecture), Tokyo Medical and Dental University Hospital (Tokyo metropolis), and Tohoku University Hospital (Miyagi prefecture). ImmunoCAP‐bovine thyroglobulin (BTG), ImmunoCAP‐beef, and IgE immunoblotting with cetuximab were performed to detect α‐Gal‐specific IgE. Clinical information was collected from participants using a questionnaire. The overall positivity rate of ImmunoCAP‐BTG was 4.0% without significant inter‐institute differences, whereas that for ImmunoCAP‐beef was 9.7% with a significant inter‐institute difference. Tokyo Medical and Dental University Hospital (19.0%) had the highest positivity rate. The positivity rate based on cetuximab IgE immunoblotting was 2.7%, without any significant inter‐institute differences. The overall positivity rate for both ImmunoCAP‐BTG and cetuximab immunoblotting was 2.0%, with a significant inter‐institute difference; 5.0% of Shimane University Hospital was the highest. Two cases showed sensitization against the non‐α‐Gal epitope of cetuximab. The overall positivity rate for both ImmunoCAP‐beef and cetuximab immunoblotting was 1.3%, without significant inter‐institute differences. Male sex was associated with positive beef‐specific IgE. The prevalence of subclinical sensitization to α‐Gal is estimated at 2.0%–4.0% in Japan and may be higher in rural areas, supporting an association between tick bites and α‐Gal sensitization. In contrast, the prevalence of subclinical sensitization to beef is 9.7% in Japan and is highest in Tokyo Metropolis, suggesting the presence of another IgE‐binding epitope apart from α‐Gal and another sensitization route in the sensitization to beef IgE. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Characterization of rosacea patients in Tohoku area of Japan: Retrospective study of 340 rosacea cases.
- Author
-
Wada‐Irimada, Moyuka, Yamamoto, Haruka, Terui, Hitoshi, Omori‐Shimada, Ryoko, Yamazaki, Emi, Kikuchi, Katsuko, Aiba, Setsuya, and Yamasaki, Kenshi
- Abstract
Rosacea is a chronic inflammatory skin disease with facial redness and acne‐like papules and pustules. The characteristics and background of rosacea patients in Japan have not been well documented. In this study, we retrospectively collected the medical information of rosacea patients, and investigated the background, complications, exacerbating factors, and status of allergy. Between January 2010 and December 2020, 431 cases were diagnosed as rosacea or rosacea‐like dermatitis. We selected 340 patients, in which we could confirm telangiectasia on facial skin. Females and males numbered 266 and 74, respectively. The average age of the first visit was 51.5 years, and the youngest and oldest were 11 and 88 years old. Among 340 cases, 323 had erythematotelangiectatic rosacea, 97 papulopustular rosacea, 20 phymatous rosacea presenting as rhinophyma, and four had symptoms of ocular rosacea. The most common complication was hay fever (93 individuals, 27.4%), and 66 (19.4%) had a medical history of contact dermatitis. Temperature differences (141 individuals, 41.5%) were the most common exacerbating factor followed by sunlight exposure (60 individuals, 17.6%). Seventy‐eight individuals received allergen‐specific immunoglobulin (Ig)E tests, and IgE for cedar was the most frequently observed (46 individuals, 59.0%). High frequencies of IgE for Dermatophagoides pteronyssinus or D. farinae (33 individuals, 42.3%) and house dust I (31 individuals, 39.7%) suggested that environmental conditions at home would affect rosacea symptoms. Since the facial skin is exposed to environmental stimuli every moment, this retrospective observation suggested the importance of the daily lifestyle guidance as well as medical treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Ehlers–Danlos syndrome type IV with a novel COL3A1 exon 14 skipping variation confirmed by Tohoku Medical Megabank Organization genomic database.
- Author
-
Shido, Kosuke, Kojima, Kaname, Yoshida‐Akai, Saaya, Kikuchi, Katsuko, Hatamochi, Atsushi, Aiba, Setsuya, and Yamasaki, Kenshi
- Abstract
A novel COL3A1 variant was identified in a Japanese case of Ehlers–Danlos syndrome type IV (EDS‐IV) with a characteristic "Madonna" face, fragile uterus, and easy bruising in addition to a history of cavernous sinus fistula. We confirmed variable diameters of collagen fibrils in the dermis and decrease in type 3 collagen production from cultured fibroblasts. Genomic DNA sequencing of the COL3A1 region and COL3A1 cDNA sequence expressing in cultured fibroblasts identified that a nucleotide variation at c.951+2T>G on intron 14 leads to skipping of exon 14 in COL3A1 cDNA. The novel variation in the splice site of COL3A1 region g.IVS14+2T>G was not listed in the EDS‐IV pathogenic genetic databases including Human Gene Mutation Database, ClinVar, and Leiden Open Variation Database. Using the whole genome sequence database of 8380 Japanese individuals reported by the Tohoku Medical Megabank Organization (ToMMo) cohort study, we also confirmed that COL3A1 g.IVS14+2T>G was not a common single nucleotide variation in the Japanese population, although 13 EDS‐related COL3A1 variants were identified in the ToMMo database of 8380 Japanese individuals. These results demonstrated that our case of EDS‐IV was a result of the novel variation of COL3A1 g.IVS14+2T>G. These statistical genetics approaches with the combination of the ToMMo database of 8380 Japanese individuals and pathogenic genetic databases are a useful method to confirm the uniqueness of novel variation in Japanese. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients.
- Author
-
Sugiura, Riichiro, Terui, Hitoshi, Shimada‐Omori, Ryoko, Yamazaki, Emi, Tsuchiyama, Kenichiro, Takahashi, Toshiya, Aiba, Setsuya, and Yamasaki, Kenshi
- Abstract
Psoriasis is a chronic disease centered on tumor necrosis factor (TNF), interleukin (IL)‐23, and IL‐17 axis. While psoriasis patients benefit from biologics targeting TNF, IL‐17s, and IL‐23 nowadays, suppression of these molecules could modulate the balances of immune systems. However, the incidence of autoimmune disease and T‐helper 2 reaction during biologic treatments for psoriasis patients is not well documented. We retrospectively examined antinuclear antibody (ANA), eosinophil counts, and immunoglobulin E (IgE) levels for psoriasis patients who underwent biologic treatments in our dermatology clinic from June 10, 2010 to January 29, 2020. A cumulative total of 199 biologic treatments were performed for a total of 128 psoriasis patients. Compared to the non‐biologic group of 109 psoriasis patients who received non‐biologic treatment, patients treated with infliximab showed more incidents of high ANA (14%, p = 0.039) and high eosinophils (14%, p = 0.021). The use of brodalumab increased incidents of high eosinophils (21%, p = 0.005) but did not affect increase in ANA and IgE. The increase in high IgE level was observed significantly more during the use of risankizumab (15%, p = 0.011). Methotrexate was the most frequently used concomitant systemic treatment, but methotrexate did not affect ANA, eosinophil counts, and IgE levels. Since the biologics for psoriasis treatment modulate the balance of T‐helper cells, careful observation is required to detect unexpected changes of systemic immune conditions under biologic treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Body mass index, HbA1c and serum C‐reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital‐based retrospective case‐control study.
- Author
-
Terui, Hitoshi, Asano, Masayuki, Shimada‐Omori, Ryoko, Tsuchiyama, Kenichiro, Takahashi, Toshiya, Nasu‐Tamabuchi, Mei, Hagiwara‐Takita, Akiko, Kusakari, Yoshiyuki, Ohtani, Tomoyuki, Aiba, Setsuya, and Yamasaki, Kenshi
- Abstract
Biologics has had a great impact on psoriasis treatment as well as the life of psoriasis patients. Infliximab (IFX), one of the biologics targeting tumor necrosis factor (TNF), is the first of the biologics introduced to Japanese psoriasis patients. Many patients had benefits of IFX from initial applications and sustained remission of skin lesions and arthritis. Some, however, fall into so‐called secondary failure, in which patients become less responsive to IFX when the treatment is repeated. The mechanism of secondary failure and the background of patients with secondary failure have not been completely elucidated. To address this issue, we retrospectively evaluated psoriasis patients treated with IFX in our department. In this retrospective, single‐center, case‐control study based on the clinical record, a total of 34 patients were enrolled. We excluded 7 patients who discontinued IFX because of adverse events of IFX. We divided other 27 patients into two groups; 16 patients who kept using IFX (Continuance group); and 11 patients who switched to other treatments (Discontinuance group). Among various clinical features, body mass index (BMI), HbA1c, and serum CRP level were significantly higher in the Discontinuance group than the Continuance group. The results indicated that these three clinical features of BMI, HbA1c and serum CRP level before treatment are the predictors of successful IFX treatment and suggest that improvement of metabolic conditions contributes to avoiding secondary failure and discontinuance of IFX. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. 2020 guidelines for the diagnosis and treatment of prurigo.
- Author
-
Satoh, Takahiro, Yokozeki, Hiroo, Murota, Hiroyuki, Tokura, Yoshiki, Kabashima, Kenji, Takamori, Kenji, Shiohara, Tetsuo, Morita, Eishin, Aiba, Setsuya, Aoyama, Yumi, Hashimoto, Takashi, and Katayama, Ichiro
- Abstract
Prurigo is a treatment‐resistant skin disease characterized by multiple isolated papules/nodules that cause severe itch. Prurigo papules/nodules occur either as primary lesions or as secondary lesions due to persistent scratching. The fundamental concepts and classifications of prurigo have not been sufficiently established, and considerable confusion remains regarding this topic. Clinical guidelines for chronic prurigo in Japan were published in 2012 in an attempt to reduce confusion regarding the concepts of prurigo and to standardize laboratory tests and treatments. However, the diagnostic terms for prurigo and associated concepts have changed over time, and new forms of treatment are under development. We have, thus, updated and revised the guidelines to classify prurigo based on clinical forms and causes, and disease name classifications based on the clinical form have been further simplified, such as prurigo nodularis, prurigo chronica multiformis, and prurigo (not otherwise specified). Expressions for acute, subacute, and chronic forms are not used. These guidelines outline the current concepts and specify treatments for prurigo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. 2020 guidelines for the diagnosis and treatment of cutaneous pruritus.
- Author
-
Satoh, Takahiro, Yokozeki, Hiroo, Murota, Hiroyuki, Tokura, Yoshiki, Kabashima, Kenji, Takamori, Kenji, Shiohara, Tetsuo, Morita, Eishin, Aiba, Setsuya, Aoyama, Yumi, Hashimoto, Takashi, and Katayama, Ichiro
- Abstract
The mechanisms underlying itch are not fully understood. Physicians usually encounter difficulty controlling itch in generalized pruritus. Since only a small percentage of patients with generalized pruritus respond to antihistamines (H1 receptor antagonists), a variety of itch mediators and mechanisms other than histaminergic signals are considered to be involved in itch for these non‐responsive patients. In 2012, we created guidelines for generalized pruritus. Those guidelines have been updated and revised to make some of the definitions, diagnostic terms, and classifications more applicable to daily clinical practice. Cutaneous pruritus as designated in these guidelines is a disease characterized by itch without an observable rash. Generalized pruritus (without skin inflammation) is defined as the presence of itch over a wide area, and not localized to a specific part of the body. This entity includes idiopathic pruritus, pruritus in the elderly, symptomatic pruritus, pregnancy‐associated pruritus, drug‐induced pruritus, and psychogenic pruritus. Localized pruritus (without skin inflammation) represents fixed itch localized to a specific part of the body, and includes anogenital pruritus, scalp pruritus, notalgia paresthetica, and brachioradial pruritus. These guidelines outline the current concepts and specify the diagnostic methods/treatments for cutaneous pruritus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy.
- Author
-
Okuma, Takami, Furudate, Sadanori, Kambayashi, Yumi, Hashimoto, Akira, Aiba, Setsuya, and Fujimura, Taku
- Abstract
BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapeutic regimens for the treatment of advanced BRAF‐mutant melanoma. Although the NCCN guideline for cutaneous melanoma recommended BRAF/MEK inhibitors as first‐line therapies for unresectable BRAF‐mutated melanoma, resistance to these drugs should be taken into account in real‐world practice. Therefore, development of a protocol for BRAF/MEK inhibitor‐resistant advanced melanoma is needed. In this report, a case of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma that was successfully treated with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy (IMRT) is reported. In the present case, not only the locally irradiated lesion, but remote metastases including inguinal lymph nodes decreased after ipilimumab plus nivolumab followed by IMRT treatment leading to complete remission, suggesting that IMRT triggered an abscopal response. Moreover, immunohistochemical analysis showed increased CD3+, CD4+, and CD8+ T cells after radio‐immunotherapy (RIT). This case suggests that RIT might break the tolerance in the tumor microenvironment and induce a systemic anti‐melanoma immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Pediatric psoriasis induced by HLA‐B46‐Cw1 haplotype: A retrospective study of psoriasis onset after hematopoietic stem cell transplantation.
- Author
-
Terui, Hitoshi, Yamasaki, Kenshi, Hagiwara‐Takita, Akiko, Shimada‐Omori, Ryoko, Tsuchiyama, Kenichiro, Saito‐Nanjo, Yuka, Rikiishi, Takeshi, Sasahara, Yoji, and Aiba, Setsuya
- Abstract
Genome‐wide association studies have identified more than 60 susceptibility loci for psoriasis, highlighting the role of genetics in psoriasis development. Although the HLA region is suggested as the most prominent susceptibility locus, the role of the HLA haplotype in the development of psoriasis is unclear. The aim of this study is to investigate how HLA haplotype changes affect the onset of psoriasis and which HLA haplotypes are associated with the development of psoriasis. A longitudinal, retrospective case series study of children was conducted at Tohoku University Hospital in Japan, between November 1981 and October 2020. We evaluated a total of 378 pediatric patients who underwent hematopoietic stem cell transplantation in the Department of Pediatrics. The background of these patients and their HLA haplotypes before and after transplantation was assessed. Among the 378 cases, aged 0–22 years old (median age 6) identified, 117 cases received autologous transplantation, 260 cases received allogeneic transplantation, and one case received syngeneic transplantation. Only two cases developed de novo psoriasis, and these cases had acquired HLA‐B46‐Cw1 after allogeneic transplantation. Others who had HLA‐B46‐Cw1 before and after allogeneic transplantation did not develop psoriasis. Our findings suggest that the HLA‐B46 and HLA‐Cw1 combination contributes to the development of psoriasis in this Asian population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients.
- Author
-
Wada‐Irimada, Moyuka, Tsuchiyama, Kenichiro, Sasaki, Rui, Hatchome, Naokazu, Watabe, Akiko, Kimura, Yutaka, Yamasaki, Kenshi, and Aiba, Setsuya
- Abstract
Systemic corticosteroid is indicated for vitiligo, especially for generalized and progressive vitiligo. However, no consensus exists yet for the dosages and modalities of systemic corticosteroid treatments for vitiligo. The purpose of this study is to validate the efficacy and safety of i.v. methylprednisolone pulse therapy (IVMP) for patients with progressive generalized vitiligo. We retrospectively reviewed the medical records of vitiligo patients treated in our institute for 10 years between January 2010 and December 2019. Among 525 vitiligo patients treated in 10 years, 33 vitiligo patients (aged, 8–78 years; 18 female and 15 males) received IVMP, a single course of daily 500 mg methylprednisolone application (8 mg/kg/day for children) for 3 consecutive days. We observed that 14 of 25 (56%) achieved stable condition without lesion progression, and 12 of 19 (63%) had more than 25% repigmentation at 6 months after IVMP. A group of Vitiligo Area Scoring Index over 10 included more patients with Vitiligo Disease Activity Score of +3 and +4 disease progression at 6 months after the IVMP. We did not observe any severe adverse events relating to the IVMP procedures. In conclusion, IVMP is a safe and effective treatment for progressive generalized vitiligo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
- Author
-
Tsutsui, Keita, Kikuchi, Katsuko, Nozawa, Keiko, Takashima, Atsuo, Tsuchiyama, Kenichiro, Namikawa, Kenjiro, Aiba, Setsuya, and Yamazaki, Naoya
- Abstract
The most common adverse event of epidermal growth factor receptor inhibitors, used to treat colorectal, non‐small cell lung, and head and neck cancers, is acneiform eruption, with a profound effect on treatment continuation. Prolonged acneiform eruptions treated with topical corticosteroids, a standard management, may be associated with secondary bacterial infections, thus there is a need for new treatments. We conducted a multicenter, phase II trial to evaluate the efficacy and safety of topical benzoyl peroxide for epidermal growth factor receptor inhibitor‐induced prolonged acneiform eruptions. Patients with colorectal, non‐small lung cell, and head and neck cancers who received epidermal growth factor receptor inhibitors for >10 weeks and had persistent acneiform eruptions were eligible. Topical benzoyl peroxide was applied to the affected area of the face once daily for 8 weeks; a clinical evaluation was performed every 2 weeks. The primary endpoint was a change in acneiform eruption severity evaluated between disease onset and end of the treatment period. The quality of life of patients was assessed using the Dermatology Life Quality Index. Of the 14 enrolled patients, 11 completed the trial. The protocol‐specified grade of acneiform eruptions from baseline to week 8 improved from 2.0 to 1.0 (P < 0.01). The dermatology life quality index score from baseline to week 8 improved from 3.0 to 1.0 point (P < 0.01). No patient experienced severe adverse events. Overall, topical benzoyl peroxide may be effective for treating and managing prolonged acneiform eruptions induced by epidermal growth factor receptor inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma.
- Author
-
Muto, Yusuke, Ryo, Eijitsu, Namikawa, Kenjiro, Takahashi, Akira, Ogata, Dai, Fujimura, Taku, Yatabe, Yasushi, Aiba, Setsuya, Yamazaki, Naoya, and Mori, Taisuke
- Subjects
MERKEL cell carcinoma ,GENETIC mutation ,PROGNOSIS ,OVERALL survival ,METASTASIS ,KERATIN - Abstract
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine carcinoma that tends to show local recurrence and metastasis. Typically, MCC is polyomavirus (MCPyV)‐associated and cytokeratin 20 (CK20) positive. However, little is known about this tumor and its origins. Here, we aimed to determine the developmental origins of MCC and to identify prognostic clinicopathologic factors. Initial examinations revealed that CK20 and MCPyV expression (CK20+, MCPyV+ (60%); CK20+, MCPyV− (10%); CK20−, and MCPyV− (30%)) did not affect overall survival. With RB1 gene sequencing of FFPE specimens, which covered an entire exon, all RB1 mutation‐positive cases showed positive regional lymph node and/or distant metastases (8/8 cases, 100%), whereas the frequency of the metastasis was statistically significantly lower in RB1 mutation‐negative cases, (10/16 cases, 62%, P = 0.033). The results were also confirmed with immunohistochemistry, and either RB1 alterations, entire exon sequencing, or immunohistochemistry was associated with the metastasis (P = 0.007). RB1 alterations may be used to access the aggressive clinical course of MCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid.
- Author
-
Ohuchi, Kentaro, Fujimura, Taku, Lyu, Chunbing, Amagai, Ryo, Muto, Yusuke, and Aiba, Setsuya
- Abstract
CXCL13 recruits CXCR5+ follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs. Tfh cells activate B cells to produce antibodies during humoral immune responses. Indeed, as previous reports suggested, CXCR5+ cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5+ cells was positively correlated with the anti‐BP180‐NC16A titers. From the above findings, in this report, we hypothesized that a chemokine related to CXCR5+ cells, namely CXCL13, may play a role in the development of BP. We performed immunohistochemical staining of CXCR5, CXCL13, LL37, CXCL10 and CCL20 for 10 cases of BP and 10 cases of pemphigus vulgaris (PV), and quantitatively analyzed the staining by digital microscopy. Moreover, we investigated the CXCL10 and CXCL13 production in BP and PV patients by enzyme‐linked immunosorbent assay. The immunomodulatory effects of LL37 on the production of T‐helper 17‐related chemokines were evaluated using monocyte‐derived M2 macrophages. Immunohistochemical staining and digital microscopic analysis showed that the ratios of CXCR5+, CXCL13+ and LL37+ cells in the dermis were significantly higher in BP patients than in PV patients. Notably, the ratio of CXCL13+ cells was positively correlated with the anti‐BP180‐NC16A titers. Moreover, the serum levels of CXCL13 were positively correlated with the anti‐BP180‐NC16A titers. Furthermore, CD163+ M2 macrophages stimulated by LL37 in vitro produced CXCL10 and CCL20. In the lesional skin of BP, CD163+ macrophages CXCL10 and CCL20 were produced. The serum levels of CXCL10 were negatively correlated with the anti‐BP180‐NC16A titers. The present study results indicate that the mechanism of the development of BP may involve the CXCL13/CXCR5‐mediated migration of Tfh cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Case series of BRAF‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
- Author
-
Fujimura, Taku, Yoshino, Koji, Kato, Hiroshi, Fujisawa, Yasuhiro, Nakamura, Yoshiyuki, Yamamoto, Yuki, Kunimoto, Kayo, Ito, Takamichi, Matsushita, Shigeto, Maekawa, Takeo, Ohuchi, Kentaro, Amagai, Ryo, Muto, Yusuke, Furudate, Sadanori, Kambayashi, Yumi, Hashimoto, Akira, and Aiba, Setsuya
- Abstract
The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.
- Author
-
Amagai, Ryo, Fujimura, Taku, Muto, Yusuke, Kambayashi, Yumi, Furudate, Sadanori, Ohuchi, Kentaro, Okuma, Takami, Hashimoto, Akira, and Aiba, Setsuya
- Subjects
CHEMOKINES ,JUVENILE idiopathic arthritis ,SERUM ,T cells ,BIOMARKERS ,MELANOMA - Abstract
Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon‐inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune‐related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Serum CCL22 levels decreased in parallel with disease activity in CCR4‐positive mycosis fungoides treated with mogamulizumab.
- Author
-
Ohuchi, Kentaro, Fujimura, Taku, Lyu, Chunbing, Amagai, Ryo, Muto, Yusuke, and Aiba, Setsuya
- Subjects
ANTIBODY-dependent cell cytotoxicity ,MYCOSIS fungoides ,CUTANEOUS T-cell lymphoma ,CHEMOKINE receptors ,SERUM - Abstract
Mogamulizumab is a humanized anti‐C‐C chemokine receptor type (CCR)4 antibody that shows cytotoxicity against CCR4+ lymphoma cells via antibody‐dependent cell‐mediated cytotoxicity in advanced cutaneous T cell lymphoma (CTCL) patients. The production levels of ligands for CCR4, that is, Chemokine (C‐C motif) ligand (CCL)17 and CCL22, are important for the assessment of the disease activity in CTCL patients. We evaluated the serum levels of CCL17, CCL19, CCL22, C‐X‐C motif chemokine ligand (CXCL)10, and CXCL13, which are ligands for CCR4, CCR7, CCR4, C‐X‐C Motif Chemokine Receptor (CXCR)3, and CXCR5, respectively, at baseline and 4 weeks after the administration of mogamulizumab in five patients with mycosis fungoides. The serum levels of CCL22 were significantly decreased in patients who responded to mogamulizumab, but no differences were identified in the serum levels of CCL17, CCL19, CXCL10, or CXCL13. Immunofluorescence staining revealed that the majority of CCL22‐producing cells were cluster of differentiation (CD)163+ tumor‐associated macrophages, and they were surrounded by CCR4+ CTCL cells. Our present data suggested that the serum CCL22 level may be a predictive marker of the efficacy of mogamulizumab for the treatment of CCR4+ CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Psoriatic arthritis with skin lesions localized to the scalp: A case report.
- Author
-
Akaishi, Tetsuya, Yamasaki, Kenshi, Mori, Yu, Takahashi, Toshiya, Izumiyama, Takuya, Terui, Hitoshi, Abe, Michiaki, Takayama, Shin, Aiba, Setsuya, and Ishii, Tadashi
- Subjects
ECZEMA ,ARTHRITIS ,PSORIATIC arthritis ,DANDRUFF ,PSORIASIS ,SCALP ,PAIN - Abstract
A 66‐year‐old man with a 2‐year history of suspected scalp eczema with excessive dandruff developed painful swollen joints in the extremities. Four months after developing polyarthritis and polydactylitis, eczema gradually spread to the face. He was referred to our hospital for intractable scalp and facial eczema and polyarthritis. Based on the appearance of the head and facial skin lesions, psoriasis was suspected. Treatment with apremilast (a phosphodiesterase‐4‐inhibitor) was initiated, which swiftly alleviated the skin lesions. The joint deformities persisted, but the pain in the joints disappeared. This case implies that psoriatic arthritis should be suspected even if psoriatic skin lesions are localized to the scalp. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Successful treatment of mogamulizumab‐resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
- Author
-
Ohuchi, Kentaro, Fujimura, Taku, Kambayashi, Yumi, Amagai, Ryo, Lyu, Chunbing, Tanita, Kayo, Sato, Yota, and Aiba, Setsuya
- Subjects
ANTIBODY-dependent cell cytotoxicity ,MYCOSIS fungoides ,TUMOR microenvironment ,CUTANEOUS T-cell lymphoma ,T-cell lymphoma ,TREATMENT effectiveness ,ANTINEOPLASTIC agents - Abstract
Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody‐dependent cell‐mediated cytotoxicity (ADCC) in advanced cutaneous T‐cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for the treatment of advanced CTCL, its efficacy is unsatisfactory, especially in mycosis fungoides (MF). Therefore, additional drugs to enhance the antitumor effects of mogamulizumab are needed to further optimize its use for the treatment of MF. In this report, two cases of mogamulizumab‐resistant MF successfully treated with additional administration of etoposide are presented. Moreover, the possible mechanisms of mogamulizumab‐etoposide combined therapy for the treatment of MF were investigated based on the modulation of chemokine profiles in vivo using an EL‐4 mouse T‐cell lymphoma model. Intraperitoneal administration of etoposide significantly increased the mRNA expressions of CCL17, CXCL5, and CXCL10, suggesting that CCR4+ CTCL cells gather around the tumor‐associated macrophagess. Furthermore, the immunomodulatory effects of etoposide on the mRNA expressions of these chemokines were validated using monocyte‐derived M2 macrophages in vitro. Since mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by ADCC that depends on the contact between the lymphoma cells and the effector cells, these chemokines could enhance the therapeutic effect of mogamulizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Severe pyrexia from nivolumab‐resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
- Author
-
Amagai, Ryo, Fujimura, Taku, Kambayashi, Yumi, Sato, Yota, Tanita, Kayo, Ohuchi, Kentaro, Hashimoto, Akira, and Aiba, Setsuya
- Abstract
Various serious adverse events (AE) have been reported to occur at a high rate in patients treated with BRAF plus mitogen‐activated protein kinase kinase (MEK) inhibitor combination therapy, but their subtypes differ among the BRAF/MEK inhibitors. Pyrexia or a spike of fever are well‐known AE of BRAF inhibitors, with or without MEK inhibitors, and have been reported to have a high incidence after dabrafenib/trametinib, but not after encorafenib/binimetinib. In this report, we describe three cases of severe pyrexia in nivolumab‐resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. Interestingly, in all cases, the serum levels of soluble CD163 C‐X‐C motif chemokine (CXCL)9, CXCL10 and CXCL11, which are known biomarkers for adult‐onset Still's disease (AOSD), increased in parallel with the development of pyrexia. Our present cases suggest that pyrexia caused by BRAF/MEK inhibitors may possess a similar pathophysiology as that of AOSD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Case series of cutaneous T‐cell lymphomas treated with bexarotene‐based therapy.
- Author
-
Fujimura, Taku, Sato, Yota, Tanita, Kayo, Amagai, Ryo, Shimauchi, Takatoshi, Ogata, Dai, Fukushima, Satoshi, Miyashita, Azusa, Fujisawa, Yasuhiro, Kambayashi, Yumi, and Aiba, Setsuya
- Abstract
Bexarotene is useful for both early and advanced cutaneous T‐cell lymphoma (CTCL), and is sometimes applied to ultraviolet‐tolerant early CTCL patients as one of the first‐line therapies in the real world. However, continuous administration of bexarotene is sometimes difficult because of its adverse events (AE). Development of an appropriate protocol for bexarotene that can induce a consistent response for CTCL without severe AE (SAE) is needed. We retrospectively investigated 29 Japanese cases of CTCL and evaluated the efficacy of treatment and incident ratios of all AE and SAE. Objective response rate (ORR) for the overall cohort was 65.5%. ORR of the 300 mg/m2 cohort (conventional dose) was 76.2%, while that of the 150–300 mg/body (low dose) with narrowband ultraviolet B light (NBUVB) cohort was 37.5%. Mean event‐free survival was 10.0 months for all patients, 6.7 months for the bexarotene conventional‐dose cohort and 19.1 months for the low‐dose with NBUVB cohort. The incident ratio of total SAE for all patients was 20.7%. The incident ratio of total SAE was 23.8% for the conventional‐dose cohort and 12.5% for the low‐dose with NBUVB cohort. Our present study suggests that low‐dose bexarotene plus NBUVB therapy is well‐tolerated and could be one of the optimal therapies for advanced CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Author reply to antibiotics in SAPHO syndrome.
- Author
-
Terui, Hitoshi, Segawa, Yuichiro, Otake, Eika, Omori, Ryoko, Tsuchiyama, Kenichiro, Kikuchi, Katsuko, Yamasaki, Kenshi, Aiba, Setsuya, and Asano, Yoshihide
- Published
- 2024
- Full Text
- View/download PDF
23. Ustekinumab treatment for hidradenitis suppurativa.
- Author
-
Takeda, Kana, Kikuchi, Katsuko, Kanazawa, Yoshitake, Yamasaki, Kenshi, and Aiba, Setsuya
- Abstract
Hidradenitis suppurativa (HS) is a follicular occlusive inflammatory skin disease that occurs in the axilla, groin, buttocks and vulval region. Control of the intractable inflammation is a primary goal of HS treatments. Benefit of anti‐tumor necrosis factor (TNF) antibodies against HS have been reported, and adalimumab has been approved for HS in Europe, the USA and Japan. However, the alternative therapies for anti‐TNF antibodies have not been established yet. We experienced a case of HS which developed during the infliximab treatment for Crohn's disease (CD) and was well managed by ustekinumab (UST). We reviewed the articles relating to ustekinumab treatments for HS. Twenty‐four HS patients, 16 women and eight men, have been treated with ustekinumab. The average age was 35.7 ± 10.8 years (mean ± SD). All were of Hurley stage II or III. Ten (10/24, 41.6%) had received anti‐TNF drugs including infliximab, adalimumab and etanercept prior to UST treatment for HS. Although the initial doses varied from 45 mg s.c. to 390 mg i.v., all cases were treated with 45 or 90 mg s.c. every 8 or 12 weeks at the regular dose, by following the regimen for psoriasis or CD. HS in most of the cases started to improve after 3–5 months of UST initiation, and some achieved complete remission. To our knowledge, our case is the first Asian HS patient improved by UST. Overall, UST is useful for HS and could be an alternative treatment if HS patients do not respond to other medications including anti‐TNF drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. A novel technique to diagnose non‐melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors.
- Author
-
Fujimura, Taku, Okabe, Takahiro, Tanita, Kayo, Sato, Yota, Lyu, Chunbing, Kambayashi, Yumi, Maruyama, Shigenao, and Aiba, Setsuya
- Subjects
THERMAL conductivity measurement ,SKIN cancer ,MELANOMA ,SKIN temperature ,SURFACE temperature ,IMMUNOSTAINING ,ABSOLUTE value - Abstract
The skin surface temperature reflects the physiological state of the human body. Quantitative methods of identification of skin cancers based on accurate measurement of effective thermal conductivity (ETC) are among the promising diagnostic tools for differentiating non‐invasive and invasive melanomas before surgical treatment. To validate these findings, in this report, the diagnostic methods for invasive and non‐invasive extramammary Paget's disease (EMPD) and squamous cell carcinoma (SCC) were further tested by measuring the absolute value of skin surface temperature and the ETC of the skin. In addition, to investigate the stromal factors that might affect ETC, immunohistochemical staining for LL37, periostin (POSTN), MMP12, and MMP28 was performed. The invasive SCC and EMPD group showed a relatively higher skin surface temperature compared to the in situ SCC group. The non‐invasive EMPD and SCC group showed significantly lower values of ETC at lesions, whereas the invasive EMPD group showed significantly higher ETC values at lesions compared to healthy skin. Immunohistochemical staining showed that the percentage of LL37‐producing cells was significantly increased in invasive EMPD and SCC compared to that in non‐invasive EMPD and SCC. Moreover, Spearman's rank correlation test showed a significant inverse correlation between the percentage of MMP12‐positive cells and increased levels of ETC‐expressing areas in EMPD and SCC (r = −.5997). The present study suggested that differences in ETC could be a novel high‐accuracy diagnostic technique for non‐melanoma skin cancer, especially for detecting dermal invasion of SCC and EMPD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases.
- Author
-
Takahashi, Toshiya, Yamasaki, Kenshi, Terui, Hitoshi, Omori, Ryoko, Tsuchiyama, Kenichiro, Fujimura, Taku, and Aiba, Setsuya
- Abstract
Perifolliculitis capitis abscedens et suffodiens (PCAS) or dissecting cellulitis is a rare condition presenting deep follicular occlusions, follicular ruptures and follicular infections in the scalp area with unknown etiology, which consequently cause primary neutrophilic cicatricial alopecia by the repeated follicular inflammation. PCAS is categorized as one of the "follicular occlusion tetrad" along with hidradenitis suppurativa, acne conglobata and pilonidal cyst. In the pathogenesis of the follicular occlusion tetrad, the involvement of neutrophils and its activator tumor necrosis factor (TNF) have been discussed. Here, we report a case of PCAS that was successfully treated with adalimumab, a human anti‐TNF monoclonal antibody. This is the first Asian case of PCAS that was improved by a TNF inhibitor. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Malassezia‐derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra‐mammary Paget's disease.
- Author
-
Sato, Yota, Fujimura, Taku, Tanita, Kayo, Chunbing, Lyu, Matsushita, Shigeto, Fujisawa, Yasuhiro, Otsuka, Atsushi, Yamamoto, Yuki, Hidaka, Takanori, and Aiba, Setsuya
- Subjects
ARYL hydrocarbon receptors ,CYTOCHROME P-450 ,LIGANDS (Biochemistry) ,MALASSEZIA ,MACROPHAGE activation - Abstract
Malassezia yeast play a role in the pathogenesis of chronic dermatitis, especially in apocrine areas, by polarizing the local immunologic background to a Th2/Th17 state through aryl hydrocarbon receptor (AhR)‐dependent pathways. Extra‐mammary Paget's disease (EMPD) is an adenocarcinoma of apocrine origin, and except for cases associated with Malassezia yeast and their metabolites, the lesions typically develop in areas not exposed to environmental material. The purpose of this study was to investigate (a) the immunomodulatory effects of Malassezia metabolites on normal human keratinocytes (NHKCs), focusing on interleukin (IL)‐17 and related cytokines/chemokines (IL‐23, IL‐36γ, CCL20), (b) the expression of these factors in lesion‐affected skin in EMPD and (c) the activation of tumor‐associated macrophages (TAMs) by these factors. Malassezia metabolites augmented the expression of cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), CCL20 and IL‐36γ mRNA in NHKCs in vitro. In lesion‐affected skin of patients with EMPD, epidermal keratinocytes expressed CYP1A1 and CCL20. In addition, Paget cells expressed CCL20 and IL‐23. IL‐17–producing cells were distributed adjacent to Paget cells. Compared to healthy donors, patients with EMPD exhibited significantly increased serum levels of soluble (s)CD163, CXCL5, CXCL10 and CCL20. In addition, serum levels of sCD163 decreased significantly following tumor resection. Our study demonstrates a possible mechanism for the development of EMPD involving AhR‐mediated signalling by epidermal keratinocytes and RANKL‐induced recruitment of Th17 cells and TAMs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Three cases of nivolumab therapy‐failed advanced melanoma successfully controlled by ipilimumab with intensity‐modulated radiotherapy.
- Author
-
Amagai, Ryo, Fujimura, Taku, Kambayashi, Yumi, Sato, Yota, Tanita, Kayo, Hashimoto, Akira, and Aiba, Setsuya
- Abstract
Anti‐programmed death 1 antibody monotherapy is a first‐line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab‐resistant melanoma successfully controlled by ipilimumab with intensity‐modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Severe eczematoid and lichenoid eruption with full‐thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin.
- Author
-
Sasaki, Rui, Fujimura, Taku, Lyu, Chunbing, and Aiba, Setsuya
- Abstract
Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody–drug conjugate composed of an anti‐Nectin‐4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full‐thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy.
- Author
-
Muto, Yusuke, Fujimura, Taku, Kambayashi, Yumi, Ohuchi, Kentaro, Amagai, Ryo, Okuma, Takami, Furudate, Sadanori, Hashimoto, Akira, and Aiba, Setsuya
- Subjects
ERYTHEMA nodosum ,PERIPHERAL circulation ,MELANOMA ,MEDICAL research ,LEG ,JAPANESE people - Abstract
Dear Editor, A previous clinical study suggested that dabrafenib plus trametinib (D + T) combination therapy could cause a high rate of various AEs including skin disorders in BRAF SP V600E sp mutated advanced melanoma patients.1 Indeed, 24% (50/209) of patients treated with D + T combination therapy developed skin disorders.1 A 46-year-old woman visited our outpatient clinic with multiple erythematous nodules with pain on the extremities. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
30. Multiple angiolymphoid hyperplasia with eosinophilia on the right arm showing unusual presentation.
- Author
-
Tamabuchi, Erika, Fujimura, Taku, Lyu, Chinbing, and Aiba, Setsuya
- Subjects
EOSINOPHILIA ,BLOOD cell count ,HYPERPLASIA ,BULLOUS pemphigoid ,DIAGNOSIS - Abstract
From the above findings, our diagnosis was multiple angiolymphoid hyperplasia with eosinophilia showing unusual presentation. 4 Adler BL, Krausz AE, Minuti A, Silverberg JI, Lev-Tov H. Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): a systematic review. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
31. Short anagen syndrome: A unique short hair syndrome without any characteristic hair morphological abnormality.
- Author
-
Segawa, Yuichiro, Yamasaki, Kenshi, Otake, Eika, Kikuchi, Katsuko, and Aiba, Setsuya
- Published
- 2020
- Full Text
- View/download PDF
32. Scalp lymphangiosarcoma: A distinct skin manifestation of edematous erythema on face and scalp without subcutaneous hemorrhage or preceding condition of lymphedema.
- Author
-
Suzuki, Hiromi, Yamasaki, Kenshi, Takayama, Shin, Abe, Michiaki, Ishii, Tadashi, and Aiba, Setsuya
- Published
- 2020
- Full Text
- View/download PDF
33. Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy.
- Author
-
Fujimura, Taku, Kambayashi, Yumi, Ohuchi, Kentaro, Amagai, Ryo, Muto, Yusuke, and Aiba, Setsuya
- Subjects
MYCOSIS fungoides ,ANTIBODY-dependent cell cytotoxicity ,CUTANEOUS T-cell lymphoma ,PALMOPLANTAR keratoderma - Published
- 2020
- Full Text
- View/download PDF
34. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.
- Author
-
Fujimura, Taku, Kambayashi, Yumi, Tono, Hisayuki, Lyu, Chinbing, Ohuchi, Kentaro, Hashimoto, Akira, and Aiba, Setsuya
- Subjects
SQUAMOUS cell carcinoma ,PROGRAMMED death-ligand 1 ,SCALP ,PROGRAMMED cell death 1 receptors - Abstract
Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti‐PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti‐PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death‐ligand 1 (PD‐L1), treated with nivolumab monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Subcutaneous granulomatous reaction with eosinophil infiltration to a silicone continuous ambulatory peritoneal dialysis Tenckhoff catheter.
- Author
-
Hatchome, Naokazu, Shido, Kosuke, Kikuchi, Katsuko, Terui, Hitoshi, Oba‐Yabana, Ikuko, Mori, Takefumi, Yamasaki, Kenshi, and Aiba, Setsuya
- Subjects
DIALYSIS catheters ,PERITONEAL dialysis ,METHYL vinyl ketone ,SILICONES ,IMPLANTABLE catheters ,CATHETER-related infections - Abstract
A few reports have described cutaneous allergic reactions to peritoneal dialysis catheters during continuous ambulatory peritoneal dialysis (CAPD).[[1]] Here, we report a rare case of subcutaneous granulomatous reaction with eosinophil infiltration caused by a peritoneal dialysis catheter, and confirmed by skin tests. To the best of our knowledge, no similar case of subcutaneous granulomatous reaction with eosinophil infiltration caused by a peritoneal dialysis catheter has been reported, which was histologically confirmed by eosinophilic infiltration in skin tests. Because a catheter infection clinically resembles a subcutaneous allergic reaction, it is important to suspect CAPD catheter-related reactions if patients do not respond to antibiotics. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
36. Atopic dermatitis without serum immunoglobulin E elevation or loss‐of‐function filaggrin gene mutation in a patient with X‐linked agammaglobulinemia.
- Author
-
Yamazaki, Emi, Kikuchi, Katsuko, Sasahara, Yoji, Kono, Michihiro, Akiyama, Masashi, and Aiba, Setsuya
- Abstract
A case of atopic dermatitis (AD) with X‐linked agammaglobulinemia (XLA), which is one of the primary immunodeficiency diseases, is reported. A 12‐year‐old boy had suffered from dry skin and recurrent itchy eruptions since he was 2 years old, and he was diagnosed as having XLA at the age of 4 years. His total immunoglobulin (Ig)E level was 7 IU/mL, even with regular Ig replacement therapy. Furthermore, filaggrin (FLG) mutations known in the Japanese population were not found. His skin lesions were well controlled by the application of a mild‐class topical steroid and a moisturizer, though he developed folliculitis due to Staphylococcus aureus infection during treatment with a strong‐class topical steroid. This case suggests that the FLG mutation and IgE‐mediated sensitization are not necessary to induce AD skin manifestation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Rare manifestation of hypereosinophilic syndrome: Diffuse‐type hair loss with massive perifollicular eosinophils.
- Author
-
Suzuki, Hiromi, Fukui, Reimu, Tabata, Nobuko, and Aiba, Setsuya
- Abstract
A 46‐year‐old woman consulted our hospital with diffuse alopecia and blood eosinophilia. Histological examination of the scalp revealed dense eosinophilic infiltration around the hair follicles and in the surrounding subcutis. Oral corticosteroid was effective to reduce hair loss and blood eosinophilia, but these conditions immediately relapsed after ending treatment. In addition to alopecia, she had diarrhea and colitis showing histological findings of dense eosinophilic infiltrations in the submucosa. We diagnosed hypereosinophilic syndrome based on hypereosinophilia of blood and tissue with clinical symptoms of alopecia and diarrhea. We suppose diffuse alopecia showing massive eosinophilic infiltration around the hair follicle is a rare symptom of hypereosinophilic syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs.
- Author
-
Tanita, Kayo, Fujimura, Taku, Sato, Yota, Lyu, Chunbing, and Aiba, Setsuya
- Subjects
MINOCYCLINE ,BULLOUS pemphigoid ,CHEMOKINES ,MACROPHAGES ,IMMUNOSUPPRESSIVE agents - Abstract
Minocycline/tetracycline is clinically used for the treatment of bullous pemphigoid (BP), and its clinical benefits are superior to those of prednisolone when considering adverse events. Although the clinical benefits of minocycline/tetracycline are well known, its immunosuppressive mechanisms are still unclear. In this study, we investigated the immunomodulatory effects of traditional anti‐BP drugs (minocycline, nicotinic acid amide, dexamethasone and cyclosporine) on CD163+ M2 macrophages in vitro, with special focus on the production of CCL18 and CCL22, both of which are produced by CD163+ M2 macrophages in the lesional skin of BP and are increased in the serum of BP patients. Minocycline decreased the production of CCL22, CCL24 and CCL26 as well as CCL2 from M2 macrophages. CCL18 from M2 macrophages was decreased by dexamethasone and cyclosporine, but not decreased by minocycline. These data suggest that the clinical benefit of minocycline is partially explained by its suppressive effects against the production of specific Th2 chemokines from M2 macrophages, which should contribute to the recruitment of Th2 cells and eosinophils in the lesional skin of BP patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. Edible oil methods to remove asphalt on burns.
- Author
-
Yamazaki, Emi, Shido, Kosuke, Yamasaki, Kenshi, and Aiba, Setsuya
- Abstract
Asphalt, also known as bitumen, is a viscous liquid or a semi‐solid form of petroleum. In cases of hot liquid asphalt splash, asphalt broadly adheres to the skin surface and is hard to remove from skin. Because accidental burns from hot liquid asphalt splash rarely occur, there is no consensus about initial approaches to remove adherent asphalt from skin. We reviewed articles relating to asphalt burns and summarized methods to remove adherent asphalt from skin, including our present case in which we successfully removed adherent asphalt by edible butter and vegetable oil. We summarized information of 127 cases and classified agents used to remove asphalt in four categories: (i) medicines; (ii) health‐care products; (iii) foods; and (iv) solvents. Before the 1990s, antimicrobial topical medicines were mainly reported to treat asphalt burns but it took half a day or more to remove asphalt. Mineral oils and edible oils such as butter and vegetable oil are easily available in grocery stores and could emulsify to remove asphalt in a few hours. From the review of articles and our experience, edible oils are useful agents for the first approach to remove asphalt from the point of view of efficacy, safety, availability and expense. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Toll‐like receptors 2 and 3 enhance melanogenesis and melanosome transport in human melanocytes.
- Author
-
Koike, Saaya, Yamasaki, Kenshi, Yamauchi, Takeshi, Inoue, Mai, Shimada‐Ohmori, Ryoko, Tsuchiyama, Kenichiro, and Aiba, Setsuya
- Subjects
MELANOCYTES ,APOPTOSIS ,MELANOGENESIS ,HUMAN skin color ,CELL proliferation - Abstract
Summary: Because little is known about how the innate immune response influences skin pigmentation, we examined whether Toll‐like receptor (TLR) agonists participate in melanogenesis and melanosome transportation. We observed that TLR2/2 agonist HKLM and TLR3 agonist Poly(I:C) increased the amount of extracellular melanin from primary human epidermal melanocytes. HKLM, but not Poly(I:C), increased the melanogenic genes such as tyrosinase and dopachrome tautomerase. Poly(I:C) increased the expression of Rab27A, a molecule that facilitates melanosome transport to perimembranous actin filament. UVB irradiation induced Rab27A and melanosome transportation in a similar manner of Poly(I:C). SiRNA for TLR3 or Rab27A suppressed the perimembranous accumulation of Gp100‐positive vesicles in melanocytes and decreased melanin transfer to neighboring keratinocytes induced by both Poly(I:C) and UVB. These results suggest that the microenvironment in the epidermis and innate immune stimuli, such as microbiome and ultraviolet represented here by TLR2 and TLR3 agonists, could affect the melanogenesis in human melanocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. Two cases of dabrafenib and trametinib therapy‐failed advanced melanoma successfully controlled by nivolumab monotherapy.
- Author
-
Sato, Yota, Fujimura, Taku, Kambayashi, Yumi, Tanita, Kayo, Tono, Hisayuki, Hashimoto, Akira, and Aiba, Setsuya
- Abstract
Abstract: Although therapies for advanced melanoma have been greatly improved by the development of immune checkpoint inhibitors and BRAF/mitogen‐activated protein kinase kinase inhibitors, there are still many concerns about the administration of these novel drugs. Therefore, to combine these therapies sequentially at appropriate time points of the disease is important. In this report, we report two cases in which dabrafenib and trametinib therapy for advanced melanoma failed but were successfully controlled by nivolumab monotherapy, and investigated the sera sCD163, CCL22 and CXCL10 as biomarkers for tumor progression. Interestingly, the sera levels of sCD163, CXCL10 and CCL22, both of which are produced by activated tumor‐associated macrophages, were increased in parallel with the tumor progression in each case. Because this report presents only two cases, further data will need to be accumulated to provide more fundamental insights into the usefulness of these biomarkers for predicting disease progression in melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. Efficacy of oral cholecalciferol on rhododendrol‐induced vitiligo: A blinded randomized clinical trial.
- Author
-
Watabe, Akiko, Yamasaki, Kenshi, Asano, Masayuki, Kanbayashi, Yumi, Nasu‐Tamabuchi, Mei, Terui, Hitoshi, Furudate, Sadanori, Kakizaki, Aya, Tsuchiyama, Kenichiro, Kimura, Yutaka, Ito, Yumiko, Kikuchi, Katsuko, and Aiba, Setsuya
- Abstract
Abstract: Rhododendrol (RD), 4‐(4‐hydroxyphenyl)‐2‐butanol, inhibits melanin synthesis and has been used for skin‐whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so‐called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty‐eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)‐intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement by comparing photographic images of baseline and at 5‐month observation. Serum 25(OH)D3 of RD vitiligo patients was not significantly different from age‐matched healthy volunteers. Twenty‐two in the VD‐intervention group and 23 in the control group completed the 5‐month observation. Serum 25(OH)D3 levels were significantly increased after the 5‐month VD intervention, while the control group did not change. The improvement scores were significantly higher in the VD‐intervention group than the control group. The improvement scores were positively correlated with the serum 25(OH)D3 levels after the 5‐month intervention period but not before the treatment. This blinded randomized clinical trial showed favor in administrating 5000 IU cholecalciferol daily to RD vitiligo patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
- Author
-
Fujimura, Taku, Kakizaki, Aya, Kambayashi, Yumi, Sato, Yota, Tanita, Kayo, Lyu, Chunbing, Furudate, Sadanori, and Aiba, Setsuya
- Subjects
ANTINEOPLASTIC antibiotics ,MELANOMA treatment ,MACROPHAGES ,TUMOR microenvironment ,VINCRISTINE ,PHYSIOLOGY - Abstract
Together with regulatory T cells (Tregs), tumor-associated macrophages ( TAMs) play roles in maintaining the tumor microenvironment. Although cytotoxic antimelanoma drugs such as dacarbazine ( DTIC), nimustine hydrochloride ( ACNU) and vincristine ( VCR) have been used for the treatment of malignant melanoma as adjuvant therapy in Japan, the detailed mechanisms of their immunomodulatory effects are not fully understood. As the majority of TAMs are alternatively activated M2 macrophages that favour tumor development, the aim of this study was to elucidate the immunomodulatory effects of these reagents on human monocyte-derived M2 macrophages. First, mRNA expressions and protein production of immune checkpoint molecules, PD-L1 and chemokines by CD163
+ CD206+ M2 macrophages derived from peripheral blood mononuclear cells were investigated to determine the immunomodulatory effects of DTIC, ACNU, and VCR. DTIC and VCR significantly decreased PD-L1 mRNA expression, which was confirmed by flow cytometry. Moreover, the mRNA expression and production of CCL22 were significantly decreased by DTIC, which suggested that DTIC might suppress the recruitment of Tregs in the tumor site. Furthermore, the decreased expression of PD-L1 and production of CCL22 were validated in vivo, using the B16F10 mouse melanoma model, leading to abrogation of the suppressive function of T-cell proliferation. The present report suggests one of the possible antimelanoma mechanisms of DAV combination chemotherapy for melanoma patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
44. A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid.
- Author
-
Fujimura, Taku, Kakizaki, Aya, Furudate, Sadanori, and Aiba, Setsuya
- Subjects
PEMPHIGUS treatment ,SKIN disease treatment ,T helper cells ,CYTOKINES ,CHEMOKINES - Abstract
Pemphigus vulgaris ( PV) and bullous pemphigoid ( BP) are autoimmune blistering diseases, and substantial numbers of CD163
+ tissue-associated macrophages ( TAMs) are detected in both diseases. PV and BP possess different subsets of helper T cells, suggesting that the cytokine profiles of PV and BP might be different. The purpose of this study was to investigate the microenvironment of lesional skin and serum of PV and BP patients, focusing on the immunomodulatory factors related to TAMs, such as periostin ( POSTN), chemokines, cytokines and matrix metalloproteinases (MMPs). We first performed immunohistological staining of POSTN in PV and BP lesions. POSTN was prominent in the superficial dermis in both PV and BP lesions. Next, to validate the activation of CD163+ TAMs in PV and BP patients, we examined the serum levels of soluble (s) CD163. The serum sCD163 levels in PV and BP patients are significantly higher than in healthy controls. To further elucidate the molecular mechanisms of the effects of POSTN on CD163+ TAMs in PV and BP, we examined chemokines, MMPs and cytokines selected by DNA microarray database. The serum CXCL5 levels from PV patients are significantly higher than those in BP patients and healthy controls. The IL-36γ expression on infiltrating macrophages was prominent only in the lesional skin of PV, while the MMP12 deposition was detected in both PV and BP lesions. Our results shed light on the novel pathogenesis of PV through CD163+ TAMs. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. Glucuronides of phytoestrogen flavonoid enhance macrophage function via conversion to aglycones by β-glucuronidase in macrophages.
- Author
-
Kaneko, Atsushi, Matsumoto, Takashi, Matsubara, Yosuke, Sekiguchi, Kyoji, Koseki, Junichi, Yakabe, Ryo, Aoki, Katsuyuki, Aiba, Setsuya, and Yamasaki, Kenshi
- Subjects
GLUCURONIDASE ,ESTROGEN receptors ,FLAVONOIDS ,MACROPHAGES ,PHARMACOKINETICS - Abstract
Introduction Flavonoids are converted to inactive metabolites like glucuronides in the gut, and circulate mainly as glucuronides in blood stream, resulting in low concentrations of active aglycones in plasma. It is therefore unclear how oral flavonoids exert their effects in tissues. We recently reported the plasma pharmacokinetics of some flavonoids and suggested the possibility that the absorbed flavonoids modified macrophage functions leading to enhance bacterial clearance. We aimed to confirm their pharmacological profiles focusing on tissue macrophages. Methods Pseudoinfection was induced by intradermal injection of FITC-conjugated and killed Staphylococcus aureus into the ears of mice treated with or without genistein 7- O-glucuronide (GEN7G, 1 mg/kg, i.v.). FACS analysis was performed on single cell suspensions dispersed enzymatically from the skin lesions at 6 h post pseudoinfection to evaluate phagocytic activities of monocytes/macrophages (CD11b
+ Ly6G− ) and neutrophils (CD11b+ Ly6G+ ). Phagocytosis of the FITC-conjugated bacteria by four glucuronides including GEN7G was evaluated in cultures of mouse macrophages. Results After GEN7G injection, genistein was identified in the inflamed ears as well as GEN7G, and the phagocytic activity of CD11b+ Ly6G− cells was increased. GEN7G was converted to genistein by incubation with macrophage-related β-glucuronidase. Macrophage culture assays revealed that GEN7G increased phagocytosis, and the action was dampened by a β-glucuronidase inhibitor. Binding of aglycones to estrogen receptors (ERs), putative receptors of flavonoid aglycones, correlated to biological activities, and glucuronidation reduced the binding to ERs. An ER antagonist suppressed the increase of macrophage function by GEN7G, whereas estradiol enhanced phagocytosis as well. Conclusions This study suggests a molecular mechanism by which oral flavonoids are carried as glucuronides and activated to aglycones by β-glucuronidase in tissue macrophages, and contributes to the pharmacological study of glucuronides. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
46. Case of late-onset erythropoietic protoporphyria with myelodysplastic syndrome who has homozygous IVS3-48C polymorphism in the ferrochelatase gene.
- Author
-
Suzuki, Hiromi, Kikuchi, Katsuko, Fukuhara, Noriko, Nakano, Hajime, and Aiba, Setsuya
- Abstract
We report the case of a 42-year-old man with a 5-year history of myelodysplastic syndrome and photosensitivity who had developed painful erythema and blisters on sun-exposed sites. Histological examination of a mildly lichenified lesion on the dorsal finger revealed extensive deposits of a hyaline-like, periodic acid-Schiff-positive material around superficial dermal blood vessels. Laboratory tests showed elevated erythrocyte protoporphyrin and normal urinary porphyrins, suggesting a diagnosis of erythropoietic protoporphyria. Late-onset erythropoietic protoporphyria is rare and is usually associated with an acquired somatic mutation of the ferrochelatase gene secondary to a hematological malignancy such as myelodysplastic syndrome. DNA analysis revealed that our patient has the homozygous IVS3-48C polymorphism that is a low-expression variant of wild-type ferrochelatase allele. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
47. Positive correlation of vanilloid receptor subtype1 and prostaglandin E2 expression with pain in leiomyomas.
- Author
-
Kagimoto, Yoshiko, Yamasaki, Kenshi, Shimada‐Ohmori, Ryoko, Nan, Liu, Numata, Yukikazu, and Aiba, Setsuya
- Abstract
Cutaneous leiomyomas are benign smooth muscle tumors that are occasionally painful. The mechanism of pain related to leiomyoma is not fully understood. To investigate the possible involvement of algoneic factors in pain from cutaneous leiomyomas. We present a case of cutaneous leiomyoma with severe, diffused pain in a large area and collected 10 more specimens of cutaneous leiomyoma with or without pain in patient histories. We immunohistochemiacally examined the expression of algoneic factors: serotonin, histamin, Substance P, PGE2, BDKRB2, VR1 and CGRP. We compared the pain area and expression of algoneic factors to reveal possible correlations. We describe here a patient with a cutaneous leiomyoma 1-cm in diameter, which caused severe pain diffused throughout an area of 20-cm around the tumor. The pain completely resolved after surgical excision of the leiomyoma. We observed that the leiomyoma cells expressed CGRP, PGE2 and VR1 in this case. We found a positive correlation between VR1 and PGE2 expression in the leiomyoma cells and areas with pain around the tumors among 11 specimens in total. VR1 and PGE2 might be key algogenic substances in painful leiomyoma. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
48. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.
- Author
-
Fujimura, Taku, Kambayashi, Yumi, Furudate, Sadanori, Hidaka, Takanori, Sato, Yota, Tanita, Kayo, Tono, Hisayuki, Tsukada, Akira, Hashimoto, Akira, and Aiba, Setsuya
- Abstract
Because the efficacy rates of monotherapy with immune checkpoint inhibitors such as nivolumab or ipilimumab are not sufficient, to enhance the antitumor effects of these reagents is of great interest among dermato-oncologists. In this report, we describe two cases of multiple in-transit metastatic melanomas on the leg successfully treated with intensity-modulated radiotherapy ( IMRT) using a CyberKnife in combination with ipilimumab or nivolumab. Our cases suggested that IMRT could enhance the antitumor effects of immune checkpoint inhibitors in patients with multiple in-transit melanomas. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
49. Successful treatment of multiple eruptive adult xanthogranuloma concomitant with xanthelasma palpebrarum with probucol.
- Author
-
Ishihara‐Yusa, Shino, Fujimura, Taku, Lyu, Chunbing, Sugawara, Masayuki, Sakamoto, Kazuhiro, and Aiba, Setsuya
- Published
- 2019
- Full Text
- View/download PDF
50. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
- Author
-
Irimada, Moyuka, Fujimura, Taku, Kambayashi, Yumi, Tsukada, Akira, Takahashi, Toshiya, Hashimoto, Akira, and Aiba, Setsuya
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.